Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
Journal
Clinical lung cancer
Journal Volume
27
Journal Issue
1
Start Page
38
End Page
46
ISSN
1938-0690
Date Issued
2026-01
Author(s)
Chen, Yuh-Min
Batra, Ullas
Do, Kien Hung
Sitthideatphaiboon, Piyada
Danchaivijitr, Pongwut
Lee, Kang-Yun
Chindaprasirt, Jarin
Yang, Cheng-Ta
Chang, Gee-Chen
Charoentum, Chaiyut
Ungtrakul, Teerapat
Moran, Juan Ignacio Hernandez
Hartmaier, Ryan
Igwegbe, Ike
Gont, Alexander
Haskins, Matthew
Xu, Wanning
Riess, Jonathan W
Abstract
MET amplification is the most common resistance mechanism to first-line osimertinib. We report safety and efficacy data from a phase II study assessing savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated, MET-amplified, advanced non-small cell lung cancer (NSCLC).
Patients with EGFR-mutated, MET-amplified (MET gene copy number ≥ 5 or MET:CEP7 ratio ≥ 2), advanced NSCLC post-osimertinib were enrolled. Patients received savolitinib 300 mg once daily (QD) plus osimertinib 80 mg QD or savolitinib plus placebo. The primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included progression-free survival (PFS) and safety. Exploratory analysis included retrospective efficacy assessment by higher MET cutoffs (immunohistochemistry 3+ staining ≥ 90% tumor cells and / or MET gene copy number ≥ 10).
Thirty patients were randomized (14 savolitinib-osimertinib; 16 savolitinib-placebo). Among all patients, ORR (95% confidence interval [CI]) was 57% (29-82) versus 13% (2-38); median PFS (95% CI) was 7.4 months (5.6-not calculable [NC]) versus 1.6 months (1.3-4.1) for savolitinib-osimertinib and savolitinib-placebo, respectively. In patients with higher MET cutoffs, ORR was 63% (24-91) and 29% (4-71); median PFS was 8.2 months (4.1-NC) and 4.0 months (1.3-NC) for savolitinib-osimertinib (n = 8) and savolitinib-placebo (n = 7), respectively. There were no new safety signals. This study was terminated early and the contribution of osimertinib to savolitinib is being assessed further in SAVANNAH (NCT03778229) in patients with higher MET biomarker cutoffs.
Savolitinib plus osimertinib demonstrated numerically higher clinical activity versus savolitinib plus placebo in all patients and patients with higher MET biomarker cutoffs.
Subjects
Contribution of components
EGFR-TKI
MET amplification
MET-TKI
Type
journal article